Study guide
7.1 Inflammatory Arthritides
MRCPI in General Medicine Part I Written
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Structure, Strategy & Foundation
1.1 MRCPI Part I Format, Scoring & Standard-Setting 1.2 RCPI BST Curriculum & Single-Best-Answer Exam Strategy
2 Chapter 2: Cardiology & Vascular Medicine
2.1 Acute Coronary Syndromes & Stable Angina 2.2 Tachyarrhythmias, Bradyarrhythmias & Channelopathies 2.3 Heart Failure & Valvular Heart Disease 2.4 Hypertension, Vascular & Pericardial Diseases
3 Chapter 3: Respiratory Medicine
3.1 Asthma, COPD & Airway Diseases 3.2 Pneumonia, Tuberculosis & Respiratory Infections 3.3 Interstitial Lung Disease & Pleural Disorders 3.4 Pulmonary Embolism, Pulmonary Hypertension & Sleep Apnoea
4 Chapter 4: Gastroenterology & Hepatology
4.1 Upper & Lower GI Disorders & Inflammatory Bowel Disease 4.2 Acute & Chronic Liver Disease 4.3 Pancreatitis, Biliary Tract & GI Bleeding 4.4 Malabsorption, GI Motility & Clinical Nutrition
5 Chapter 5: Nephrology & Acid-Base Disorders
5.1 Acute Kidney Injury & Glomerular Diseases 5.2 Chronic Kidney Disease & Renal Replacement Therapy 5.3 Electrolyte Imbalances & Acid-Base Disorders
6 Chapter 6: Endocrinology & Diabetes
6.1 Diabetes Mellitus & Metabolic Complications 6.2 Thyroid & Calcium Disorders 6.3 Adrenal, Pituitary & Endocrine Syndromes
7 Chapter 7: Rheumatology & Clinical Immunology
7.1 Inflammatory Arthritides 7.2 Systemic Autoimmune & Vasculitic Diseases 7.3 Metabolic Bone Disease & Clinical Immunology
8 Chapter 8: Haematology & Medical Oncology
8.1 Anaemias, Haemostasis & Thrombosis 8.2 Leukaemias, Lymphomas & Plasma Cell Disorders 8.3 Medical Oncology & Oncological Emergencies
9 Chapter 9: Neurology & Dermatology
9.1 Stroke & Cerebrovascular Diseases 9.2 Epilepsy, Headache & Movement Disorders 9.3 Neuromuscular & Peripheral Nerve Disorders 9.4 Cutaneous Manifestations of Systemic Disease
10 Chapter 10: Acute Medicine, Critical Care & Geriatrics
10.1 Acute Poisoning & Toxidromes 10.2 Sepsis, Shock & Resuscitation 10.3 Geriatric Syndromes, Frailty & Comprehensive Care
11 Chapter 11: Clinical Pharmacology & Therapeutics
11.1 Pharmacokinetics & Pharmacodynamics 11.2 High-Risk Drug Classes & Prescribing Safety 11.3 Adverse Drug Reactions & Drug Safety
12 Chapter 12: Basic Sciences, Biostatistics & Clinical Ethics
12.1 Applied Cardiovascular & Respiratory Physiology 12.2 Clinical Biochemistry, Molecular Genetics & Microbiology 12.3 Biostatistics, Evidence-Based Medicine & Ethics
7.1 Inflammatory Arthritides
Key Takeaways Explain This Topic AI
Anti-cyclic citrullinated peptide (anti-CCP / ACPA) antibodies demonstrate 96–98% specificity for Rheumatoid Arthritis and predict aggressive erosive disease.
Methotrexate (10–25 mg weekly SC/oral) is the anchor csDMARD; Folic acid 5 mg weekly must be co-prescribed on a separate day (24–48 hours post-methotrexate).
Ankylosing Spondylitis is strongly associated with HLA-B27 (~90%); a modified Schober test demonstrating <5 cm lumbar expansion indicates restricted spinal mobility.
Monosodium urate crystals are strongly negatively birefringent and needle-shaped; target serum urate during urate-lowering therapy is <360 µmol/L (<300 µmol/L in tophaceous gout).
Calcium pyrophosphate deposition (CPPD) crystals are weakly positively birefringent and rhomboid-shaped, associated with chondrocalcinosis, hyperparathyroidism, and hemochromatosis.
Last updated: July 2026
7.1 Inflammatory Arthritides
Inflammatory arthritides represent a diverse group of systemic immune-mediated disorders targeting the synovium, entheses, and articular cartilage. Mastery of clinical patterns, serological profiling, radiographic hallmarks, and pharmacotherapeutic hierarchies is essential for MRCPI General Medicine candidates.
- Rheumatoid Arthritis (RA)
- Pathophysiology & Synovial Pannus
Rheumatoid Arthritis (RA) is a chronic, systemic autoimmune disease characterized by persistent symmetric polyarthritis. Autoimmune targeting of modified self-proteins (citrullination by peptidylarginine deiminase enzymes) leads to synovial hyperplasia and infiltration by T-cells, B-cells, macrophages, and plasma cells. This hyperplastic synovial tissue forms a pannus —an invasive vascular tissue that releases matrix metalloproteinases (MMPs), interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α), causing progressive cartilage degradation and subchondral bone erosions mediated by RANKL-activated osteoclasts.
Joint Distribution & Clinical Presentation
RA predominantly affects the small joints of the hands and feet in a symmetrical distribution:
Commonly Involved Joints: Metacarpophalangeal (MCP) joints, Proximal Interphalangeal (PIP) joints, Metatarsophalangeal (MTP) joints, wrists, knees, ankles, and cervical spine (specifically C1–C2 atlantoaxial articulation).
Joints Spared (Exam Classic): Distal Interphalangeal (DIP) joints and the lumbar/thoracoabdominal spine are characteristically spared in RA.
Symptom Profile: Gel phenomenon with morning joint stiffness lasting >60 minutes , improving with movement and worsening with rest.
2010 ACR / EULAR Classification Criteria
Classification requires a score of ≥6 / 10 across four domains:
Joint Involvement: 1 large joint (0), 2–10 large joints (1), 1–3 small joints (2), 4–10 small joints (3), >10 joints with at least 1 small joint (5).
Serology: Negative RF and negative anti-CCP (0), Low-positive RF or anti-CCP (2), High-positive RF or anti-CCP (>3x upper limit of normal) (3).
Acute-Phase Reactants: Normal CRP and ESR (0), Abnormal CRP or ESR (1).
Duration of Symptoms: <6 weeks (0), ≥6 weeks (1).
Serological Markers
Rheumatoid Factor (RF): IgM autoantibody directed against the Fc region of human IgG. Sensitivity: ~70–80%. Specificity: ~70–75%. RF is elevated in other non-rheumatic conditions (infective endocarditis, hepatitis C, chronic liver disease, Sjögren syndrome, and healthy elderly).
Anti-Citrullinated Protein Antibodies (anti-CCP / ACPA): Sensitivity: ~70–75%. Specificity: 96–98% . Anti-CCP positivity is a key prognostic marker indicating aggressive, erosive disease, accelerated extra-articular manifestations, and worse radiological progression.
Extra-Articular Manifestations
Rheumatoid Nodules: Subcutaneous central fibrinoid necrosis surrounded by palisading histiocytes, occurring over extensor surfaces (olecranon process, Achilles tendon) in ~25% of seropositive patients.
Felty Syndrome: Triad of severe seropositive RA , splenomegaly , and neutropenia (<1.5 × 10⁹/L) . High risk of recurrent bacterial infections and cutaneous ulceration.
Caplan Syndrome: Combination of rheumatoid arthritis and pneumoconiosis, presenting with multiple basilar rheumatoid pulmonary nodules in miners.
Pulmonary: Pleural effusion (characteristically low glucose <1.6 mmol/L, low pH, high LDH), Usual Interstitial Pneumonia (UIP) / Interstitial Lung Disease (ILD), and pulmonary nodules.
Cardiovascular: Pericarditis (most common cardiac manifestation), accelerated coronary atherosclerosis, and myocarditis.
Neurological: Cervical spine subluxation (atlanto-axial instability presenting with neck pain, quadriparesis, or Lhermitte sign); entrapment neuropathies (carpal tunnel syndrome).
- Pharmacotherapy & Treatment Hierarchy [Early Presentation / Suspected RA]
- │
- ▼
- [First-Line csDMARD Monotherapy / Combination]
- Methotrexate (10–25 mg/week SC/oral)
- Co-prescribe Folic Acid 5 mg/week (24–48h post-MTX)
- Short-course Bridging Corticosteroids
- │
- Failure / Intolerance after 3–6 months
- ▼
- [Add / Switch csDMARDs]
- Leflunomide or Sulfasalazine or Hydroxychloroquine
- │
- Inadequate Response + High Disease Activity (DAS28 >5.1)
- ▼
- [Initiate Biologic DMARD (bDMARD) or Targeted Synthetic (tsDMARD)]
- TNF Inhibitors (Adalimumab, Etanercept, Infliximab)
- IL-6 Receptor Antagonist (Tocilizumab)
- Anti-CD20 Monoclonal (Rituximab — preferred in seropositive RA)
- JAK Inhibitors (Tofacitinib, Baricitinib, Upadacitinib)
Exam Pearl: Before initiating any TNF inhibitor or biologic agent, candidates MUST screen for latent Tuberculosis (Interferon-Gamma Release Assay / Mantoux + Chest X-ray) and Hepatitis B / C . If latent TB is identified, complete 1 month of chemoprophylaxis (isoniazid) before starting the TNF inhibitor.
Seronegative Spondyloarthropathies (SpA)
The seronegative spondyloarthropathies share a common genetic background ( HLA-B27 association), absence of Rheumatoid Factor/anti-CCP, inflammation of entheses (enthesitis), axial skeleton involvement (sacroiliitis, spondylitis), and asymmetrical peripheral oligobarthritis.
Axial Spondyloarthritis & Ankylosing Spondylitis (AS)
Epidemiology: Predominantly young males (ratio 2:1 to 3:1), onset typically <45 years.
Inflammatory Back Pain Criteria: Insidious onset, duration >3 months, morning stiffness >30 minutes, improves with exercise , no improvement with rest , and frequent awakening during the second half of the night due to pain.
Physical Examination Metrics:
Modified Schober Test: Mark a baseline 10 cm line above S2 (spinous process between PSIS). Measure distance on maximal forward flexion. An expansion of <5 cm (total distance <15 cm) indicates significant lumbar spine restriction.
Occiput-to-Wall Distance: Normally 0 cm; increased in progressive kyphosis.
Chest Expansion: Measured at 4th intercostal space; <2.5 cm is abnormal.
Radiographic Findings: Bilateral sacroiliitis (grade ≥2 bilateral or grade 3–4 unilateral), marginal syndesmophytes (vertical bony bridges across intervertebral discs), Romanus lesions (anterior spondylitis shiny corners), and the classic "bamboo spine" appearance.
Extra-Spinal Manifestations:
Acute Anterior Uveitis (30–40%): Unilateral, painful red eye with photophobia and blurred vision.
Cardiovascular: Aortic regurgitation (aortitis causing aortic root dilation) and cardiac conduction blocks.
Pulmonary: Apical pulmonary fibrosis (often misdiagnosed as tuberculosis).
Renal: Secondary AA Amyloidosis and IgA nephropathy.
Management: First-line treatment is continuous high-dose NSAIDs . Biologic therapy with TNF inhibitors (Adalimumab, Etanercept) or IL-17A inhibitors (Secukinumab) is indicated for active axial disease refractory to NSAIDs. Note: Conventional synthetic DMARDs (methotrexate, sulfasalazine) are ineffective for isolated axial disease!
Psoriatic Arthritis (PsA)
CASPAR Criteria: Requires established inflammatory articular disease plus ≥3 points from: current psoriasis (2 pts) or personal/family history (1 pt), psoriatic nail dystrophy (1 pt), negative RF (1 pt), dactylitis (1 pt), and juxta-articular new bone formation on radiography (1 pt).
Five Clinical Subtypes:
Asymmetrical oligoarthritis (<5 joints involved; most common ~70%).
Symmetrical polyarthritis (RA-like distribution, but RF-negative and DIP-involved).
DIP joint predominant disease (strongly linked with nail dystrophy).
Axial spondyloarthritis (asymmetrical syndesmophytes, non-marginal).
Arthritis Mutilans: Severe osteolysis resulting in telescoping digits ("opera-glass hands") and "pencil-in-cup" deformity on plain radiographs.
Key Features: Dactylitis ("sausage digit"), Achilles enthesitis, plantar fasciitis, and nail changes (nail pitting >20 pits, onycholysis, oil-drop discoloration).
Reactive Arthritis (ReA)
Definition: Sterile autoimmune arthritis occurring 1 to 6 weeks following a mucosal gastrointestinal or genitourinary infection.
Classic Triad (Reiter Syndrome): Urethritis/cervicitis, Conjunctivitis, and Asymmetrical lower-limb Oligoarthropathy.
Trigger Pathogens:
Genitourinary: Chlamydia trachomatis (most common overall).
Gastrointestinal: Shigella flexneri , Salmonella enterica , Yersinia enterocolitica , Campylobacter jejuni .
Cutaneous Manifestations: Keratoderma blennorrhagica (hyperkeratotic vesicopustular skin lesions on palms and soles) and Circinate balanitis (painless erythematous erosions on the glans penis).
Management: NSAIDs first-line. Prompt antibiotic treatment for active Chlamydia infection (does not shorten arthritis duration once established). Refractory chronic arthritis (>6 months) requires csDMARDs (Sulfasalazine or Methotrexate).
Enteropathic Arthritis
Associated with Inflammatory Bowel Disease (Crohn disease and Ulcerative Colitis):
Type 1 (Pauciarticular): Affects <5 joints, asymmetrical, strongly correlates with bowel disease activity (treating gut flares resolves the peripheral joint swelling).
Type 2 (Polyarticular): Affects ≥5 joints, symmetrical, independent of IBD flare activity.
Axial Spondyloarthritis: Mirrors ankylosing spondylitis and runs an independent clinical course from bowel inflammation.
Crystal-Induced Arthropathies
Crystal deposition in articular structures triggers intense NLRP3 inflammasome activation, cleavage of pro-interleukin-1β, and rapid neutrophil recruitment, causing acute exquisite monoarthritis.
Gout
Pathophysiology: Hyperuricemia resulting from urate overproduction (10%) or renal underexcretion (90%). Serum urate >360 µmol/L (>6.0 mg/dL) exceeds physiological saturation, precipitating monosodium urate (MSU) crystals in joints and avascular tissues (tophi).
Risk Factors: Male sex, metabolic syndrome, chronic kidney disease, loop/thiazide diuretics, excessive alcohol (beer/spirits), high-fructose diets, purine-rich foods (red meat, seafood), and cytotoxic chemotherapy (tumor lysis syndrome).
Synovial Fluid Analysis: Strongly negatively birefringent , needle-shaped intracellular and extracellular crystals under polarized light microscopy. Synovial WBC count 2,000–50,000/µL with >50–80% neutrophils.
Radiographic Hallmarks: Punched-out juxta-articular erosions with sclerotic borders and overhanging cortical margins ("Martel sign"); preservation of joint space until late stages.
Acute Flare Management:
First-line: High-dose NSAIDs (e.g., Naproxen, Indomethacin), Colchicine (500 mcg bd to tds; microtubule polymerization inhibitor; side effect: severe dose-dependent diarrhea), or oral/intra-articular Corticosteroids .
Critical Rule: Do NOT initiate or stop Urate-Lowing Therapy (ULT) during an acute flare, as abrupt serum urate fluctuations prolong the attack. Continue existing ULT if already established.
Urate-Lowering Therapy (ULT):
Indications: ≥2 flares per year, presence of tophi, renal impairment (CKD), urolithiasis, or young age (<40 years).
Target Serum Urate: <360 µmol/L (<6.0 mg/dL) for uncomplicated gout; <300 µmol/L (<5.0 mg/dL) for tophaceous gout.
First-line Drug: Allopurinol (xanthine oxidase inhibitor; start at 100 mg daily [50 mg in CKD], titrate every 2–4 weeks by 100 mg increments up to 800 mg daily). Screening for HLA-B*5801 allele is recommended in Han Chinese, Thai, and Korean patients due to high risk of life-threatening Allopurinol Hypersensitivity Syndrome (Stevens-Johnson syndrome / TEN).
Second-line Drug: Febuxostat (non-purine xanthine oxidase inhibitor).
Mandatory Flare Prophylaxis: When starting or titrating ULT, co-prescribe low-dose Colchicine 500 mcg daily/bd or low-dose NSAID for 3 to 6 months to prevent mobilization flares.
Calcium Pyrophosphate Deposition (CPPD) / Pseudogout
Pathophysiology: Deposition of calcium pyrophosphate dihydrate crystals within cartilage, menisci, and synovium.
Synovial Fluid Analysis: Weakly positively birefringent , rhomboid-shaped crystals under polarized light microscopy.
Radiographic Findings: Chondrocalcinosis (punctate linear calcification within articular fibrocartilage, menisci of knees, triangular fibrocartilage of wrist, and symphysis pubis).
Metabolic Workup for Underlying Triggers: Candidates presenting with CPPD <60 years must be screened for:
Primary Hyperparathyroidism (Elevated Ca²⁺, low PO₄³⁻, elevated PTH).
Hereditary Hemochromatosis (Elevated transferrin saturation >45%, elevated ferritin; characteristic 2nd/3rd MCP joint degenerative changes with hook-like osteophytes).
Hypomagnesemia and Hypophosphatasia .
Acute Management: Intra-articular corticosteroid injection (preferred for single large joint), oral NSAIDs, or low-dose oral colchicine.
Synovial Fluid Analysis Diagnostic Matrix
Parameter Normal Non-Inflammatory (e.g., OA) Inflammatory (RA, SpA, Gout) Septic Arthritis
Clarity / Color Clear / Transparent Clear / Straw yellow Translucent / Cloudy yellow Opaque / Purulent / Green-yellow
- Viscosity Very High High Low Very Low
- WBC Count (/µL) <200 200–2,000 2,000–50,000 >50,000 (often >100,000)
- Neutrophils (%) <25% <25% >50% >75% (often >90%)
- Microscopy No crystals No crystals MSU (Neg needle) or CPPD (Pos rhomboid) Bacteria on Gram stain (>50–70%)
Glucose (mmol/L) Equal to blood Equal to blood Decreased (<2.2 mmol/L) Markedly low (<1.5 mmol/L or <50% serum)